SILK ROAD MEDICAL INC (SILK) Stock Price & Overview

NASDAQ:SILK • US82710M1009

Current stock price

27.49 USD
-0.01 (-0.04%)
At close:
27.49 USD
0 (0%)
After Hours:

The current stock price of SILK is 27.49 USD. Today SILK is down by -0.04%. In the past month the price increased by 1.36%. In the past year, price increased by 74.98%.

SILK Key Statistics

52-Week Range6.08 - 27.51
Current SILK stock price positioned within its 52-week range.
1-Month Range27 - 27.51
Current SILK stock price positioned within its 1-month range.
Market Cap
1.117B
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-1.44
Dividend Yield
N/A

SILK Stock Performance

Today
-0.04%
1 Week
+1.51%
1 Month
+1.36%
3 Months
+1.93%
Longer-term
6 Months +47.64%
1 Year +74.98%
2 Years -38.91%
3 Years -50.05%
5 Years -15.49%
10 Years N/A

SILK Stock Chart

SILK ROAD MEDICAL INC / SILK Daily stock chart

SILK Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to SILK. When comparing the yearly performance of all stocks, SILK is one of the better performing stocks in the market, outperforming 90.01% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

SILK Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to SILK. The financial health of SILK is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SILK Earnings

On August 7, 2024 SILK reported an EPS of -0.42 and a revenue of 51.24M. The company missed EPS expectations (-9.6% surprise) and beat revenue expectations (1.28% surprise).

Next Earnings DateNov 6, 2024
Last Earnings DateAug 7, 2024
PeriodQ2 / 2024
EPS Reported-$0.42
Revenue Reported51.242M
EPS Surprise -9.60%
Revenue Surprise 1.28%

SILK Forecast & Estimates

13 analysts have analysed SILK and the average price target is 22.54 USD. This implies a price decrease of -18% is expected in the next year compared to the current price of 27.49.

For the next year, analysts expect an EPS growth of -3.77% and a revenue growth 16.35% for SILK


Analysts
Analysts49.23
Price Target22.54 (-18.01%)
EPS Next Y-3.77%
Revenue Next Year16.35%

SILK Groups

Sector & Classification

Index Membership

SILK Financial Highlights

Over the last trailing twelve months SILK reported a non-GAAP Earnings per Share(EPS) of -1.44. The EPS decreased by -2.13% compared to the year before.


Income Statements
Revenue(TTM)191.44M
Net Income(TTM)-56.54M
Industry RankSector Rank
PM (TTM) N/A
ROA -20.96%
ROE -36.55%
Debt/Equity 0.49
Chartmill High Growth Momentum
EPS Q2Q%-20%
Sales Q2Q%13.12%
EPS 1Y (TTM)-2.13%
Revenue 1Y (TTM)17.54%

SILK Ownership

Ownership
Inst Owners3.3%
Shares40.63M
Float38.94M
Ins Owners28.49%
Short Float %N/A
Short RatioN/A

About SILK

Company Profile

SILK logo image Silk Road Medical, Inc. engages in the development and manufacturing of medical devices to treat neurovascular diseases. The company is headquartered in Sunnyvale, California and currently employs 474 full-time employees. The company went IPO on 2019-04-04. The firm has developed an approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. Its product portfolio consists of five single-use components: ENROUTE Transcarotid Neuroprotection System, ENROUTE Transcarotid Stent System, ENHANCE Transcarotid Peripheral Access Kit, ENROUTE 0.014'' Guidewire and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter. The company manufactures ENROUTE NPS and ENROUTE NPS PLUS, or its ENROUTE NPS products, at its facilities in Sunnyvale, California and Plymouth, Minnesota. These facilities provide an aggregate of over 35,000 square feet of space for its production and distribution operations.

Company Info

IPO: 2019-04-04

SILK ROAD MEDICAL INC

1213 Innsbruck Dr

Sunnyvale CALIFORNIA 94089 US

CEO: Erica J. Rogers

Employees: 474

SILK Company Website

Phone: 16505669060

SILK ROAD MEDICAL INC / SILK FAQ

What does SILK do?

Silk Road Medical, Inc. engages in the development and manufacturing of medical devices to treat neurovascular diseases. The company is headquartered in Sunnyvale, California and currently employs 474 full-time employees. The company went IPO on 2019-04-04. The firm has developed an approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. Its product portfolio consists of five single-use components: ENROUTE Transcarotid Neuroprotection System, ENROUTE Transcarotid Stent System, ENHANCE Transcarotid Peripheral Access Kit, ENROUTE 0.014'' Guidewire and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter. The company manufactures ENROUTE NPS and ENROUTE NPS PLUS, or its ENROUTE NPS products, at its facilities in Sunnyvale, California and Plymouth, Minnesota. These facilities provide an aggregate of over 35,000 square feet of space for its production and distribution operations.


What is the stock price of SILK ROAD MEDICAL INC today?

The current stock price of SILK is 27.49 USD. The price decreased by -0.04% in the last trading session.


Does SILK ROAD MEDICAL INC pay dividends?

SILK does not pay a dividend.


How is the ChartMill rating for SILK ROAD MEDICAL INC?

SILK has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


What is the GICS sector and industry of SILK stock?

SILK ROAD MEDICAL INC (SILK) operates in the Health Care sector and the Health Care Equipment & Supplies industry.


Would investing in SILK ROAD MEDICAL INC be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SILK.